ERBB4 and cancer: Moreover, by using the same evaluation criteria, we identify new biomarkers whose impact on drug response spans multiple cancers, including SALL4, B2M, BAP1, CCDC6, ERBB4, FOXA1, GRIN2A, and PTPRT.